Glaxosmithkline Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 180.00 Cr
- Paid Up Capital ₹ 169.41 Cr
- Company Age 100 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 21.87 Cr
- Satisfied Charges ₹ 130.00 Cr
- Revenue Growth 6.42%
- Profit Growth -3.79%
- Ebitda 12.66%
- Net Worth 1.77%
- Total Assets 6.61%
About Glaxosmithkline Pharmaceuticals
Glaxosmithkline Pharmaceuticals Limited (GPL) was founded in India on 13 November 1924 and has a glorious history of 100 years and three months. Its registered office is in Mumbai, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 500660 and on the National Stock Exchange(NSE) under GLAXO.
The Corporate was formerly known as British Drug Houses (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 180.00 Cr and a paid-up capital of Rs 169.41 Cr.
The company currently has active open charges totaling ₹21.87 Cr. The company has closed loans amounting to ₹130.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Glaxosmithkline Pharmaceuticals Limited India are Ajay Nadkarni as COMPANY SECRETARY and Juby Chandy as Cfo. Juby Chandy, Bhushan Akshikar, Subesh Williams, and Five other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
Industry
Who are the key members and board of directors at Glaxosmithkline Pharmaceuticals?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Bhushan Akshikar ![]() | Managing Director | 01-Dec-2022 | Current |
Ajay Nadkarni ![]() | Company Secretary | 01-Nov-2001 | Current |
Juby Chandy | CFO | 01-Apr-2022 | Current |
Board Members (7)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sunitha Maheshwari ![]() | Director | 18-May-2020 | Current |
Sundaram Damodarannair ![]() | Director | 27-Jul-2009 | Current |
Subesh Williams ![]() | Director | 07-Apr-2017 | Current |
Renu Karnad ![]() | Director | 01-Apr-2019 | Current |
Manu Anand ![]() | Director | 16-May-2022 | Current |
Anami Roy ![]() | Director | 04-Nov-2011 | Current |
Financial Performance of Glaxosmithkline Pharmaceuticals.
Glaxosmithkline Pharmaceuticals Limited, for the financial year ended 2024, experienced modest growth in revenue, with a 6.42% increase. The company also saw a slight decrease in profitability, with a 3.79% decrease in profit. The company's net worth moved up by a moderate rise of 1.77%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Glaxosmithkline Pharmaceuticals?
In 2023, Glaxosmithkline Pharmaceuticals had a promoter holding of 75.00% and a public holding of 25.01%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹21.87 Cr
₹130.00 Cr
Charges Breakdown by Lending Institutions
- The Hongkong And Shanghai Banking Corporation Ltd. : 21.87 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
13 Jul 1989 | The Hongkong And Shanghai Banking Corporation Ltd. | ₹21.87 Cr | Open |
20 Sep 2004 | Uti Bank Ltd. | ₹130.00 Cr | Satisfied |
How Many Employees Work at Glaxosmithkline Pharmaceuticals?
Glaxosmithkline Pharmaceuticals has a workforce of 505 employees as of Dec 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Glaxosmithkline Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glaxosmithkline Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.